Ocugen receives provisional Bahamas clearance for OCU400 access pathway
Ocugen ($OCGN) received provisional approval and priority designation from the Bahamas’ Longevity and Regenerative Therapies Board for OCU400, its experimental gene therapy for retinitis pigmentosa. The company intends to supply the treatment through an expanded-access program, with the goal of treating an initial patient within 90 days after full approval from that regulator. The provisional decision creates a pathway toward local access; it is not the final authorization required to start the
0